Literature DB >> 20393461

Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.

Toru Kobayashi1, Kazuo Washiyama, Kazutaka Ikeda.   

Abstract

Atomoxetine and reboxetine are commonly used as selective norepinephrine reuptake inhibitors (NRIs) for the treatment of attention-deficit/hyperactivity disorder and depression, respectively. Furthermore, recent studies have suggested that NRIs may be useful for the treatment of several other psychiatric disorders. However, the molecular mechanisms underlying the various effects of NRIs have not yet been sufficiently clarified. G-protein-activated inwardly rectifying K(+) (GIRK or Kir3) channels have an important function in regulating neuronal excitability and heart rate, and GIRK channel modulation has been suggested to be a potential treatment for several neuropsychiatric disorders and cardiac arrhythmias. In this study, we investigated the effects of atomoxetine and reboxetine on GIRK channels using the Xenopus oocyte expression assay. In oocytes injected with mRNA for GIRK1/GIRK2, GIRK2, or GIRK1/GIRK4 subunits, extracellular application of atomoxetine or reboxetine reversibly reduced GIRK currents. The inhibitory effects were concentration-dependent, but voltage-independent, and time-independent during each voltage pulse. However, Kir1.1 and Kir2.1 channels were insensitive to atomoxetine and reboxetine. Atomoxetine and reboxetine also inhibited GIRK currents induced by activation of cloned A(1) adenosine receptors or by intracellularly applied GTPgammaS, a nonhydrolyzable GTP analogue. Furthermore, the GIRK currents induced by ethanol were concentration-dependently inhibited by extracellularly applied atomoxetine but not by intracellularly applied atomoxetine. The present results suggest that atomoxetine and reboxetine inhibit brain- and cardiac-type GIRK channels, revealing a novel characteristic of clinically used NRIs. GIRK channel inhibition may contribute to some of the therapeutic effects of NRIs and adverse side effects related to nervous system and heart function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393461      PMCID: PMC3055469          DOI: 10.1038/npp.2010.27

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  62 in total

1.  Reduced ethanol-induced conditioned taste aversion and conditioned place preference in GIRK2 null mutant mice.

Authors:  Katherine G Hill; Herminia Alva; Yuri A Blednov; Christopher L Cunningham
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

Review 2.  G protein-activated inwardly rectifying potassium channels as potential therapeutic targets.

Authors:  Toru Kobayashi; Kazutaka Ikeda
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

3.  Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation.

Authors:  Norio Hashimoto; Toru Yamashita; Nobutomo Tsuruzoe
Journal:  Pharmacol Res       Date:  2006-04-01       Impact factor: 7.658

4.  Isolated atomoxetine (Strattera) ingestions commonly result in toxicity.

Authors:  Frank Lovecchio; J Kashani
Journal:  J Emerg Med       Date:  2006-10       Impact factor: 1.484

5.  The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice.

Authors:  Todd H Ahern; Martin A Javors; Douglas A Eagles; Jared Martillotti; Heather A Mitchell; Larry Cameron Liles; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2006-04       Impact factor: 7.853

6.  Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial.

Authors:  Susan L McElroy; Anna Guerdjikova; Renu Kotwal; Jeffrey A Welge; Erik B Nelson; Kathleen A Lake; Paul E Keck; James I Hudson
Journal:  J Clin Psychiatry       Date:  2007-03       Impact factor: 4.384

Review 7.  Antidepressants and seizures: emphasis on newer agents and clinical implications.

Authors:  S A Montgomery
Journal:  Int J Clin Pract       Date:  2005-12       Impact factor: 2.503

8.  G protein-activated inwardly rectifying K+ channel inhibition and rescue of weaver mouse motor functions by antidepressants.

Authors:  Takehiro Takahashi; Toru Kobayashi; Miwako Ozaki; Yukio Takamatsu; Yasukazu Ogai; Mitsuaki Ohta; Hideko Yamamoto; Kazutaka Ikeda
Journal:  Neurosci Res       Date:  2005-11-28       Impact factor: 3.304

9.  Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  J Pharmacol Sci       Date:  2006-10-28       Impact factor: 3.337

10.  Synthesis and evaluation of radioiodinated (S,S)-2-(alpha-(2-iodophenoxy)benzyl)morpholine for imaging brain norepinephrine transporter.

Authors:  Naoki Kanegawa; Yasushi Kiyono; Hiroyuki Kimura; Taku Sugita; Satomi Kajiyama; Hidekazu Kawashima; Masashi Ueda; Yuji Kuge; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-08       Impact factor: 9.236

View more
  8 in total

1.  Layer- and area-specificity of the adrenergic modulation of synaptic transmission in the rat neocortex.

Authors:  Swagata Roychowdhury; Amy N Zwierzchowski; Francisco Garcia-Oscos; Roberto Cuevas Olguin; Roberto Salgado Delgado; Marco Atzori
Journal:  Neurochem Res       Date:  2014-09-30       Impact factor: 3.996

Review 2.  Beta-Cell Ion Channels and Their Role in Regulating Insulin Secretion.

Authors:  Benjamin Thompson; Leslie S Satin
Journal:  Compr Physiol       Date:  2021-10-12       Impact factor: 9.090

Review 3.  In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder.

Authors:  Edna Grünblatt; Jasmin Bartl; Zoya Marinova; Susanne Walitza
Journal:  J Neural Transm (Vienna)       Date:  2012-07-26       Impact factor: 3.575

4.  Paroxetine suppresses recombinant human P2X7 responses.

Authors:  Phuong Dao-Ung; Kristen K Skarratt; Stephen J Fuller; Leanne Stokes
Journal:  Purinergic Signal       Date:  2015-09-05       Impact factor: 3.765

5.  Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

6.  Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner.

Authors:  Karl Josef Föhr; Ariadni Nastos; Michael Fauler; Thomas Zimmer; Bettina Jungwirth; David Alexander Christian Messerer
Journal:  Front Pharmacol       Date:  2021-02-25       Impact factor: 5.810

Review 7.  Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.

Authors:  Cintya Nirvana Dutta; Leonardo Christov-Moore; Hernando Ombao; Pamela K Douglas
Journal:  Front Hum Neurosci       Date:  2022-09-26       Impact factor: 3.473

8.  Pathway analysis in attention deficit hyperactivity disorder: An ensemble approach.

Authors:  Michael A Mooney; Shannon K McWeeney; Stephen V Faraone; Anke Hinney; Johannes Hebebrand; Joel T Nigg; Beth Wilmot
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-03-22       Impact factor: 3.568

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.